Navigation Links
Noninvasive ways to assess liver disease
Date:2/1/2008

Two new studies examine non-invasive ways to determine liver fibrosis and cirrhosis. An enhanced version of the Original European Liver Fibrosis panel was found to have good diagnostic accuracy for fibrosis in patients with non-alcoholic fatty liver disease. Conversely, transient elastography was unreliable for detecting cirrhosis in patients with acute liver damage. The studies are published in the February issue of Hepatology, a journal by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The articles are also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology).

Liver biopsy is the undisputed best way to assess liver fibrosis or cirrhosis; however, it is an invasive procedure that can cause rare, but potentially life threatening complications. Researchers have been seeking less invasive ways to diagnose liver disease, developing and testing clinical tools, like the Original European Liver Fibrosis Panel and transient elastography.

Researchers led by William Rosenberg in the United Kingdom, sought to validate the Original European Liver Fibrosis panel and consider a simplification that removed age as a factor yielding the Enhanced Liver Panel. They also tested the diagnostic performance of the ELF panel with the addition of the following simple markers: age, BMI, presence of diabetes/impaired fasting glucose, AST/ALT ratio, platelets, and albumin.

They recruited 196 patients with non-alcoholic fatty liver disease from two separate centers and tested the diagnostic accuracy of the new panels. They found that the Enhanced Liver Fibrosis panel detected severe fibrosis, moderate fibrosis and no fibrosis at AUCs of .90, .82, and .76 respectively. The diagnostic accuracy of the ELF panel plus simple markers was .98, .93 and .84 respectively. They report that using either panel could eliminate the need for liver biopsy in diagnosing severe fibrosis in more than 80 percent of cases.

The ELF panel has good diagnostic accuracy in an independent validation cohort of patients with NAFLD, the authors conclude. The addition of established simple markers augments the diagnostic performance across different stages of fibrosis, which will potentially allow superior stratification of patients with NAFLD for emerging therapeutic strategies.

Meanwhile, researchers in Germany led by Abdurrahman Sagir used transient elastographyFibroscan (FS)to measure liver stiffness in 20 patients presenting with acute hepatitis. In 15 (75 percent) of the patients, the test showed liver stiffness values that suggested cirrhosis. However, none of these patients showed any signs of cirrhosis in a physical exam, on ultrasound, or in liver histology.

Liver stiffness measurement by FS in patients with acute liver damage overestimate the real stage of fibrosis and may erroneously suggest the presence of liver cirrhosis, the authors report. The stiffness may relate to hepatocyte swelling, cholestasis, or infiltrates of inflammatory cells in the inflamed liver, they suggest.

FS results need to be interpreted with caution in patients with acute liver damage and high values of liver stiffness do not predict the simultaneous presence of cirrhosis in these patients, they conclude.

Both studies offer new information on the ability of non-invasive methods to diagnose liver disease, though further studies are needed to advance our understanding of these diagnostic tools.


'/>"/>

Contact: Amy Molnar
amolnar@wiley.com
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Breaking Study: Masimo Pleth Variability Index (PVI) Shown Effective in Noninvasive Detection of Changes in Ventricular Preload and Fluid Volume
2. Noninvasive tests for cirrhosis may help to avoid liver biopsy
3. IQWiG presents a concept for cost-benefit assessment methods in the German health care system
4. Biophysical Unveils BiophysicalCheck Health Assessment Program to Aid in Pre-Symptomatic Detection of Disease
5. Health Capital Group Warns of Fallout to Hospitals From the Subprime Mortgage Crisis and Urges Hospitals to Immediately Reassess Existing Debt Structures and Capital Financing Plans
6. Justice Department Requires Divestitures in Pearsons Acquisition of Harcourt Assessment
7. MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
8. DSS Research Announces Senior Health Risk Assessment Tool
9. MRI techniques evolving towards better assessment of liver fibrosis
10. National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment
11. SecureWorks Designated as a Qualified Security Assessor for PCI Audits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... pharmaceutical organizations to build intelligent, connected applications, was named the best Sales Team ... , The winner announcement was made today by the Software & Information Industry ...
(Date:11/30/2016)... ... 30, 2016 , ... "I hate when the mixture of saliva and toothpaste ... an inventor from Bridgewater, N.J. "I thought that there had to be a way ... developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... tech functions and stylish design wanted by today’s consumers at an affordable price, ... Darin Philip says the new watch is “a game changer” when it comes ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... R.I. , Dec. 2, 2016 CVS ... its annual Analyst Day in New York City on Thursday, December 15, ... CVS Health leadership team will provide an in-depth review ... enhance shareholder value. The company will also discuss 2017 ... and video webcast of the event will be broadcast ...
(Date:12/2/2016)... , Dec. 2, 2016 Lianluo ... Smart" or "the Company") which develops, markets and ... in China and international ... Disease Diagnosis and Treatment New Progress Forum, co-hosted ... Guangdong Province , Guangdong Provincial People,s ...
(Date:12/2/2016)... -- On Thursday, the NASDAQ Composite ended the ... Average edged 0.36% higher, to finish at 19,191.93; and the ... based as six out of nine sectors ended the day ... following Services equities: Myriad Genetics Inc. (NASDAQ: MYGN ... Holdings Inc. (NASDAQ: INCR ), and La Quinta ...
Breaking Medicine Technology: